8-K: Cutera Inc. Announces Board Resignation and Appointment

Jeryl Hilleman resigns from Cutera's board, and Paul Wierbicki is appointed as her replacement with a special compensation agreement.

Summary

• On February 12, 2025, Jeryl Hilleman resigned from Cutera, Inc.'s Board of Directors, effective immediately.
• The resignation was not due to any disagreement with the company's operations, policies, or practices.
• On February 13, 2025, Paul Wierbicki was appointed to the Board to fill the vacancy.
• Mr. Wierbicki entered into an independent director engagement agreement with a $25,000 monthly fee, with a minimum of $75,000 payable.
• The company's standard outside director compensation program is suspended for Mr. Wierbicki.
• Mr. Wierbicki has no material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.

Sentiment

Score: 6

Explanation: The announcement is neutral, detailing a board resignation and appointment. The special compensation arrangement for the new director could be seen as slightly positive or negative depending on investor perspective.

Positives

• The company quickly filled the board vacancy with the appointment of Paul Wierbicki.

Industry Context

Board changes are a normal part of corporate governance, but the specific compensation arrangement for the new director may be of interest to investors.

Comparison to Industry Standards

• Director compensation varies widely across industries and company sizes.
• A $25,000 monthly fee for a director position is relatively high, but not unheard of, especially if the director brings specific expertise or experience.
• It would be useful to compare this compensation to that of directors at comparable medical device companies.

Management Changes

Stakeholder Impact

• Shareholders may be interested in the board changes and the compensation arrangement for the new director.
• The company's management team will need to integrate the new director into the board's activities.

Key Dates